Mango Sciences Partners With ImmunoACT to Expand Access and Affordability of CAR-T Therapy for Cancer Patients in India Through Innovative Financing and Value-Based Care
Mango Sciences, Inc., a data and artificial intelligence-driven healthcare company with operations in Boston, USA, and Bengaluru, India, today announced a strategic partnership with ImmunoAdoptive Cell Therapy (ImmunoACT), India’s pioneering cell and gene therapy company based in Mumbai. The collaboration is aimed at significantly expanding access to advanced CAR-T (Chimeric Antigen Receptor T-cell) therapy for patients battling life-threatening blood cancers such as leukaemia and lymphoma across India.
Through this landmark partnership, eligible patients will gain access to a first-of-its-kind bridge financing plan combined with a value-based care offering to support treatment with ImmunoACT’s breakthrough CAR-T therapy, NexCAR19™. The initiative is designed to reduce the massive financial barrier that often prevents patients from accessing cutting-edge cancer treatments.
Under the new program, patients may avail easy 0% interest EMI (equated monthly installment) plans of up to ₹10 lakh, significantly easing the financial burden associated with CAR-T therapy. In addition, a value-based offering of up to ₹10 lakh will also be extended to clinically eligible patients, enabling outcome-based affordability aligned with therapeutic success.
Addressing a Critical Gap in Advanced Cancer Care
CAR-T therapy represents one of the most transformative advances in modern cancer treatment, particularly for patients with relapsed or refractory blood cancers that do not respond to conventional therapies. However, despite its proven effectiveness, CAR-T therapy remains financially inaccessible for a majority of patients due to its high upfront costs.
With NexCAR19™, ImmunoACT has introduced India’s first indigenously developed CAR-T therapy, dramatically lowering treatment costs compared to international alternatives while maintaining global standards of safety and efficacy. Even so, affordability continues to remain a challenge for many families.
The partnership with Mango Sciences directly targets this challenge by introducing structured, risk-sharing financial solutions that combine affordability with accountability through value-based healthcare models. This approach not only eases patient access but also represents a significant shift in how advanced therapies are funded and delivered in India.
NexCAR19 A Breakthrough in Indian Cancer Innovation
NexCAR19 is a first-of-its-kind indigenous CAR-T therapy developed specifically for Indian patients with certain types of leukaemia and lymphoma. CAR-T therapy works by genetically modifying a patient’s own T-cells to recognize and attack cancer cells with high precision.
Unlike conventional chemotherapy, which affects both healthy and cancerous cells, CAR-T therapy offers targeted immune-based treatment, often producing remarkable remission rates in patients who have exhausted other treatment options.
By developing NexCAR19™ domestically, ImmunoACT has made it possible for Indian patients to access this lifesaving innovation at a fraction of the global cost—bringing global oncology innovation closer to home.
Innovative Financing: A Global First in CAR-T Access
What sets this partnership apart on a global scale is the introduction of value-based financing for CAR-T therapy—an approach rarely seen even in developed healthcare systems.
Through Mango Sciences’ advanced data science and AI-driven risk evaluation platforms, patients’ clinical profiles and treatment eligibility will be assessed to determine participation under the financing and value-based plans. This ensures that financial assistance is deployed in a medically responsible and sustainable way.
The bridge financing option enables patients to begin treatment without the immediate burden of full upfront payment. Meanwhile, the value-based offering aligns financial support with clinical outcomes, reflecting Mango Sciences’ focus on data-backed healthcare innovation and patient-centric risk-sharing.
Initial Rollout at Select Healthcare Facilities
The Mango Sciences financing and value-based plan will initially be made available at select healthcare institutions in India that are currently administering NexCAR19™ therapy. This phased rollout is intended to ensure optimal clinical oversight, financial governance, and smooth patient onboarding before the program expands nationwide.
Patients opting for NexCAR19™ through these facilities will be guided through both the clinical eligibility assessment and financial application process, ensuring transparency and streamlined access from diagnosis through treatment.
Leadership Perspectives on the Partnership
Dr. Mohit Misra, Founder and CEO of Mango Sciences, highlighted the broader healthcare impact of this collaboration:
We are excited to bring our value-based offerings to CAR-T therapy—a global first in this space. At Mango, our mission is driven by the belief that advanced medical innovations should not be limited by affordability. By utilizing data science, AI, and innovative financing, we aim to ensure that patients can access the latest breakthroughs in oncology. Together with ImmunoACT, we are committed to improving access to innovative treatments such as CAR-T and to transforming cancer outcomes in India.”
Dr. Rahul Purwar, Founder of ImmunoACT, echoed this sentiment and emphasized the patient-centric nature of the initiative:
We are delighted to partner with Mango Sciences to improve both access and affordability for patients who need NexCAR19™. These programs will significantly help patients afford our therapy and are rooted in outcome-based principles, reflecting our strong clinical confidence and the growing body of evidence supporting NexCAR19’s safety and efficacy. Our shared vision is to ensure that no eligible patient is denied life-saving therapy due to financial constraints.”
Transforming the Economics of Cancer Treatment
This partnership reflects a broader transformation unfolding across the global healthcare landscape, where value-based care models are replacing traditional fee-for-service systems. Under value-based healthcare, treatment success, patient outcomes, and real-world effectiveness take precedence over volume-based billing.
By applying this philosophy to CAR-T therapy, Mango Sciences and ImmunoACT are redefining how advanced oncology treatments can be delivered sustainably—even in resource-constrained healthcare systems.
The integration of AI-powered analytics enables smarter patient stratification, predictive financial modeling, and outcome tracking, which together ensure optimal patient support while maintaining long-term viability for healthcare providers.
A New Hope for Leukaemia and Lymphoma Patients
Leukaemia and lymphoma collectively account for a significant proportion of cancer diagnoses in India, affecting both pediatric and adult populations. For patients who relapse after chemotherapy or bone marrow transplants, treatment options have historically been limited.
CAR-T therapy has changed that narrative globally, offering renewed hope even for late-stage patients. With NexCAR19™ and this new affordability initiative, this hope is now becoming realistically accessible to Indian families who previously could not even consider such advanced care.
Patients will now have multiple financial support pathways, including interest-free installment plans and outcome-linked financial assistance—bringing peace of mind alongside clinical care.
About Mango Sciences:
Mango Sciences is a healthcare data and AI technology company dedicated to transforming patient care through advanced data analytics and solutions. Founded by industry veterans with extensive experience in healthcare, life sciences, and data analytics, Mango Sciences is driven by a passion for improving patient representation and access to comprehensive healthcare. Mango Sciences’ Value-Based offering program is a pioneering program that reduces financial burden on cancer patients paying out-of-pocket and also allows pharmaceutical innovators to expand access to their products in a scalable and sustainable manner.
About ImmunoACT
ImmunoACT is a cell and gene therapy company that was incubated at IIT Bombay with a mission to provide affordable access to novel autologous CAR-T cell therapies for cancer treatment. It received Market Authorization from Central Drugs Standard Control Organization (“CDSCO“) in October 2023 for its lead product, namely, Actalycabtagene autoleucel (hereinafter referred to as “NexCAR19“). With a rapidly expanding pipeline beginning with blood cancers, the Company is working to expand its portfolio in solid tumours and autoimmune disorders, enabling medical professionals to provide patients with effective cancer therapy as an alternative to traditional chemotherapy, biologics, and bone marrow transplants.
source link: https://www.businesswire.com
